• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在叙利亚仓鼠SARS-CoV-2感染模型中对阿育吠陀-64(一种多草药配方)及其成分的评估揭示了其预防潜力。

Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of .

作者信息

Rizvi Zaigham Abbas, Madan Upasna, Tripathy Manas Ranjan, Goswami Sandeep, Mani Shailendra, Awasthi Amit, Dikshit Madhu

机构信息

Immuno-Biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute (THSTI), NCR-Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad 121001, India.

Immunology-Core Lab, Translational Health Science and Technology Institute (THSTI), NCR-Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad 121001, India.

出版信息

Pharmaceuticals (Basel). 2023 Sep 21;16(9):1333. doi: 10.3390/ph16091333.

DOI:10.3390/ph16091333
PMID:37765142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10534577/
Abstract

In the current study, we evaluated the efficacy of Ayush-64 (A64), a polyherbal formulation containing (L.) R. Br. (), L. (), Royle ex Benth (), and (Roxb.) H. Karst. () against COVID-19 in a Syrian hamster infection model. Preventative use of A64 resulted in the late-phase recovery of body weight loss in severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected hamsters, suppression of pro-inflammatory cytokines, and blunted pulmonary pathology. In addition, we also investigated the efficacy of individual ingredients of A64, viz., , , , and , in the hamster model. The hamster challenge data showed robust anti-viral and immunomodulatory potential in , followed by . However, and of A64 showed prominent immunomodulatory potential without limiting the lung viral load. In order to better understand the immunomodulatory potential of these herbal extracts, we used an in vitro assay of helper T cell differentiation and found that mediated a more profound suppression of Th1, Th2, and Th17 cell differentiation as compared to A64 and other ingredients. Taken together, our animal study data identifies the ameliorative potential of A64 in mitigating coronavirus disease-19 (COVID-19) pulmonary pathology. , a constituent extract of A64, showed relatively higher anti-viral and immunomodulatory potential against COVID-19. The present study warrants further investigations to identify the active pharmaceutical ingredients of for further studies.

摘要

在本研究中,我们评估了阿育吠陀-64(A64)的疗效,A64是一种含有(L.)R. Br.()、L.()、Royle ex Benth()和(Roxb.)H. Karst.()的多草药配方,在叙利亚仓鼠感染模型中对抗新型冠状病毒肺炎(COVID-19)的效果。预防性使用A64可使严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的仓鼠体重减轻在后期恢复,抑制促炎细胞因子,并减轻肺部病理变化。此外,我们还在仓鼠模型中研究了A64的各个成分,即、、、和的疗效。仓鼠攻毒数据显示,具有强大的抗病毒和免疫调节潜力,其次是。然而,A64的和显示出显著的免疫调节潜力,而不限制肺部病毒载量。为了更好地理解这些草药提取物的免疫调节潜力,我们使用了辅助性T细胞分化的体外试验,发现与A64和其他成分相比,对Th1、Th2和Th17细胞分化的抑制作用更为显著。综上所述,我们的动物研究数据确定了A64在减轻冠状病毒病-19(COVID-19)肺部病理方面的改善潜力。A64的成分提取物对COVID-19显示出相对较高的抗病毒和免疫调节潜力。本研究值得进一步调查,以确定的活性药物成分,以供进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/adebb274feb5/pharmaceuticals-16-01333-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/deac3b89426e/pharmaceuticals-16-01333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/9ed2227c776a/pharmaceuticals-16-01333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/a12f55ec0395/pharmaceuticals-16-01333-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/d74e387e36a0/pharmaceuticals-16-01333-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/1970a04f2309/pharmaceuticals-16-01333-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/adebb274feb5/pharmaceuticals-16-01333-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/deac3b89426e/pharmaceuticals-16-01333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/9ed2227c776a/pharmaceuticals-16-01333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/a12f55ec0395/pharmaceuticals-16-01333-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/d74e387e36a0/pharmaceuticals-16-01333-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/1970a04f2309/pharmaceuticals-16-01333-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7459/10534577/adebb274feb5/pharmaceuticals-16-01333-g006a.jpg

相似文献

1
Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of .在叙利亚仓鼠SARS-CoV-2感染模型中对阿育吠陀-64(一种多草药配方)及其成分的评估揭示了其预防潜力。
Pharmaceuticals (Basel). 2023 Sep 21;16(9):1333. doi: 10.3390/ph16091333.
2
Efficacy and Safety of Add-On Plant-Based Drugs for COVID-19 Patients: A Review of the Randomized Control Trials.用于新冠肺炎患者的植物源附加药物的疗效与安全性:随机对照试验综述
Infect Drug Resist. 2023 Jun 19;16:3879-3891. doi: 10.2147/IDR.S417727. eCollection 2023.
3
evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main protease.评估阿育吠陀药物AYUSH-64的化合物对新型冠状病毒主要蛋白酶的作用。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100413. doi: 10.1016/j.jaim.2021.02.004. Epub 2021 Feb 25.
4
Pharmacological potential of (L.) Dunal and (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions.(L.)Dunal 和(Willd.)Miers 在 COVID-19、T 细胞分化和中性粒细胞功能的实验模型中的药理学潜力。
Front Immunol. 2023 Mar 7;14:1138215. doi: 10.3389/fimmu.2023.1138215. eCollection 2023.
5
Anti-psoriatic potential of medicinal plants, Alstonia scholaris, Wrightia tinctoria, and Solanum xanthocarpum, using human HaCaT keratinocytes by multi-parametric analysis.药用植物夹竹桃、黄药子和酸浆抗银屑病作用的多参数分析及其对人 HaCaT 角质形成细胞的影响。
J Ethnopharmacol. 2024 Nov 15;334:118596. doi: 10.1016/j.jep.2024.118596. Epub 2024 Jul 18.
6
Prophylactic treatment of mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.预防性治疗通过抑制仓鼠模型中的促炎细胞因子和 NETosis 减轻 COVID-19 病理学。
Front Immunol. 2022 Sep 27;13:945583. doi: 10.3389/fimmu.2022.945583. eCollection 2022.
7
Alstonia scholaris (L.) R. Br. and Alstonia macrophylla Wall. ex G. Don: A comparative review on traditional uses, phytochemistry and pharmacology.印度萝芙木和大叶牛奶树:传统用途、植物化学与药理学的比较综述
J Ethnopharmacol. 2014 Apr 11;153(1):1-18. doi: 10.1016/j.jep.2014.01.025. Epub 2014 Jan 28.
8
Effects of total alkaloids from Alstonia scholaris (L.) R. Br. on ovalbumin-induced asthma mice.杠柳总生物碱对卵清蛋白诱导哮喘小鼠的影响。
J Ethnopharmacol. 2024 Jan 10;318(Pt A):116887. doi: 10.1016/j.jep.2023.116887. Epub 2023 Jul 17.
9
A polyherbal formulation, HC9 regulated cell growth and expression of cell cycle and chromatin modulatory proteins in breast cancer cell lines.一种复方草药制剂 HC9 调节乳腺癌细胞系的细胞生长和细胞周期及染色质调节蛋白的表达。
J Ethnopharmacol. 2019 Oct 5;242:112022. doi: 10.1016/j.jep.2019.112022. Epub 2019 Jun 13.
10
Pharmacological evaluation of Alstonia scholaris: anti-inflammatory and analgesic effects.夹竹桃科植物匙羹藤的药理学评价:抗炎和镇痛作用。
J Ethnopharmacol. 2010 May 27;129(2):174-81. doi: 10.1016/j.jep.2010.02.011. Epub 2010 Feb 26.

引用本文的文献

1
CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.CoviWall是一种全病毒灭活的B.1.617.2候选疫苗,可在小鼠中诱导强烈的体液和Th1细胞反应,并保护叙利亚仓鼠免受B.1.617.2毒株的攻击。
Front Immunol. 2025 Jan 22;15:1447962. doi: 10.3389/fimmu.2024.1447962. eCollection 2024.
2
Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice.草药提取物和沙罗格列他对高脂饮食诱导的C57BL/6J小鼠肥胖、胰岛素抵抗、血脂异常及肝脏脂质组的影响。
Heliyon. 2023 Nov 4;9(11):e22051. doi: 10.1016/j.heliyon.2023.e22051. eCollection 2023 Nov.

本文引用的文献

1
Pharmacological potential of (L.) Dunal and (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions.(L.)Dunal 和(Willd.)Miers 在 COVID-19、T 细胞分化和中性粒细胞功能的实验模型中的药理学潜力。
Front Immunol. 2023 Mar 7;14:1138215. doi: 10.3389/fimmu.2023.1138215. eCollection 2023.
2
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.AYUSH 64 联合标准治疗用于轻中度 COVID-19 的辅助治疗:一项随机、对照、多中心临床试验。
PLoS One. 2023 Mar 16;18(3):e0282688. doi: 10.1371/journal.pone.0282688. eCollection 2023.
3
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
一种广谱中和单克隆抗体克服了新兴的 SARS-CoV-2 关切变异株的突变景观。
PLoS Pathog. 2022 Dec 12;18(12):e1010994. doi: 10.1371/journal.ppat.1010994. eCollection 2022 Dec.
4
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.S-217622,一种新型 SARS-CoV-2 主要蛋白酶抑制剂,可降低病毒载量并改善 COVID-19 感染仓鼠的严重程度。
Sci Transl Med. 2023 Jan 18;15(679):eabq4064. doi: 10.1126/scitranslmed.abq4064.
5
effect of , AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19.阿育吠陀-64(AYUSH-64)和瑞德西韦对细胞色素P450(CYP-450)酶活性的影响:对COVID-19治疗中可能的草药-药物相互作用的启示
Front Pharmacol. 2022 Oct 12;13:973768. doi: 10.3389/fphar.2022.973768. eCollection 2022.
6
Prophylactic treatment of mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.预防性治疗通过抑制仓鼠模型中的促炎细胞因子和 NETosis 减轻 COVID-19 病理学。
Front Immunol. 2022 Sep 27;13:945583. doi: 10.3389/fimmu.2022.945583. eCollection 2022.
7
Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 - An open-label randomized controlled pilot study.阿育吠陀64作为轻度新冠肺炎标准治疗辅助药物的影响——一项开放标签随机对照试验研究。
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100587. doi: 10.1016/j.jaim.2022.100587. Epub 2022 May 18.
8
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India.AYUSH-64 联合标准治疗用于轻度至中度 COVID-19:印度昌迪加尔的一项开放性随机对照试验。
Complement Ther Med. 2022 Jun;66:102814. doi: 10.1016/j.ctim.2022.102814. Epub 2022 Feb 8.
9
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.严重急性呼吸综合征冠状病毒2型奥密克戎变异株B.1.1.529可导致广泛的中和抗体反应逃逸。
Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.
10
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.